# US 2014/0371238 A1 · Compounds and methods for the treatment of cystic fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0371238 A1
- Document ID: US20140371238A1
- Status: Published application
- Kind: A1
- Application number: 14/210,238
- Filed: 2014-03-13
- Published: 2014-12-18
- Earliest claimed: 2013-03-13
- Assignees: Flatley Discovery Lab, LLC
- Applicants: Flatley Discovery Lab
- Inventors: Michael P. Zawistoski; Yevgen Barsukov; Bridget M. Cole; Richard A. Nugent
- Web page: https://patentgrep.com/patent/US20140371238A1

## CPC

- C07D 211/96: Sulfur atom
- A61K 31/4245: Oxadiazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/443: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:

## Claims

### Claim 1

A compound of Formula I or an ester or prodrug thereof:
wherein n is 0, 1, 2, 3, 4, 5, 6 or 7;
each X is independently selected from —CR100, —N—, —COR100, —CN(R100)(R101), —CSR100—C—C(O)NR100, and —CN(R100)C(O)R101;
A1 is absent, —[C(R100)(R101)]— —C(O)—, —C(S)—, —S(O)—, —C(O)N(R100)— or —S(O)2—, —S(O)2N(R100)(R101), —N[C(R100)(R101)]m—, —N(R100)C(O)—, —N(R100)C(S)—, —N(R100)S(O)—, —N(R101)C(O)N(R100)— or —N(R100)S(O)2—, —N(R100)S(O)2N(R100)(R101);
wherein m is 0, 1, 2, 3, 4, 5, 6 or 7;
wherein each R100 and R101 is hydrogen, deuterium, halogen, alkyl, cycloalkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl and substituted aryl, heterocycle, substituted heterocycle, heteroaryl or substituted heteroaryl; alternatively two of R100 and R101 groups together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;
A2 is absent, —[C(R100)(R101)]m— —C(O)—, —C(S)—, —S(O)—, —C(O)N(R100)— or —S(O)2—, —S(O)2N(R100)(R101);
each R1 is independently selected from hydrogen, deuterium, halogen, alkyl, cycloalkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl —OR100, —SR100, —S(O)—, S(O)2—, —S(O)2N(R100)(R101), —NR100R101, —C(O)R100, —C(O)OR100, —C(O)NR100R101, —N(R100)C(O)R101, —CF3, —CN, —NO2, —N3, acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, alkylthio or substituted alkylthio; alternatively two of R1 groups together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted 3, 4, 5, 6 or 7 membered ring;
Cy1 is absent, alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
wherein when Cy1 is phenyl and A1 is absent or C1-C4 alkyl, the phenyl group is substituted with a group selected from halogen, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl —OR100, —SR100, —S(O)—, S(O)2—, —S(O)2N(R100)(R101) —NR100R101, —C(O)R100, —C(O)OR100, —C(O)NR100R101, —N(R100)C(O)R101, —CF3, —CN, —NO2, —N3, acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, alkylthio or substituted alkylthio;
wherein when Cy1 is cyclobutyl, cyclopentyl or furan, Cy2 is substituted with a group other than —OCF3, —CF3, —OCH3, —Cl or —F; and,
Cy2 is alkyl, cycloalkyl, substituted cycloalkyl aryl, substituted aryl, heteroaryl or substituted heteroaryl.

### Claim 2

A compound of Formula IA or an ester or prodrug thereof:
wherein n is 0, 1, 2, 3, 4, 5, 6 or 7;
each X is independently selected from each X is independently selected from —CR100—, —N—, —COR100, —CN(R100)(R101), —CSR100, —C—C(O)NR100, and —CN(R100)C(O)R101;
A1 is absent, —[C(R100)(R101)]m— —C(O)—, —C(S)—, —S(O)—, —C(O)N(R100)— or —S(O)2—, —S(O)2N(R100)(R101), —N[C(R100)(R101)]m—, —N(R100)C(O)—, —N(R100)C(S)—, —N(R100)S(O)—, —N(R101)C(O)N(R100)— or —N(R100)S(O)2—, —N(R100)S(O)2N(R100)(R101);
wherein m is 0, 1, 2, 3, 4, 5, 6 or 7;
wherein each R100 and R101 is hydrogen, deuterium, halogen, alkyl, cycloalkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl and substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl or substituted heteroaryl; alternatively two of R100 and R101 groups together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;
A2 is absent, —[C(R100)(R101)]m— —C(O)—, —C(S)—, —S(O)—, —C(O)N(R100)— or —S(O)2—, —S(O)2N(R100)(R101);
each R1 is independently selected from hydrogen, deuterium, halogen, alkyl, cycloalkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl —OR100, —SR100, —S(O)—, —S(O)2—, —S(O)2N(R100)(R101) —NR100R101, —C(O)R100, —C(O)OR100, —C(O)NR100R101, —N(R100)C(O)R101, —CF3, —CN, —NO2, —N3, acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, alkylthio or substituted alkylthio; alternatively two of R1 groups together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted 3, 4, 5, 6 or 7 membered ring;
Cy1 is absent, alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
Cy2 is alkyl, cycloalkyl, substituted cycloalkyl aryl, substituted aryl, heteroaryl or substituted heteroaryl.

### Claim 3 (depends on 1)

A compound of claim 1 having the Formula II or HA:

### Claim 4 (depends on 1)

A compound of claim 1 having the formula:
wherein p is 0, 1, 2 or 3;
each R2 is independently selected from hydrogen, deuterium, halogen, alkyl, cycloalkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl —OR100, —SR100, —S(O)—, S(O)2—, —S(O)2N(R100)(R101), —NR100R101, —C(O)R100, —C(O)OR100, —C(O)NR100R101, —N(R100)C(O)R101, —CF3, —CN, —NO2, —N3, acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, alkylthio or substituted alkylthio; and,
R3 is selected from halogen, deuterium, alkyl, substituted alkyl, cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl —OR100, —SR100, —S(O)—, —S(O)2—, —S(O)2N(R100)(R101), —NR100R101, —C(O)R100, —C(O)OR100, —C(O)NR100R101, —N(R100)C(O)R101, —CF3, —CN, —NO2, —N3, acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, alkylthio or substituted alkylthio; alternatively, two of R2 groups or an R2 group with an R3 group together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted 3, 4, 5, 6 or 7 membered ring.

### Claim 5 (depends on 1)

A compound of claim 1 having the formula:
wherein q is 0, 1, 2 or 3;
each R4 is independently selected from hydrogen, deuterium, halogen, alkyl, cycloalkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl —OR100, —SR100, —S(O)—, S(O)2—, —S(O)2N(R100)(R101), —NR100R101, —C(O)R100, —C(O)OR100, —C(O)NR100R101, —N(R100)C(O)R101, —CF3, —CN, —NO2, —N3, acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, alkylthio or substituted alkylthio; and,
R5 is selected from hydrogen, deuterium, halogen, alkyl, substituted alkyl, cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl —OR100, —SR100, —S(O)—, —S(O)2—, —S(O)2N(R100)(R101), —NR100R101, —C(O)R100, —C(O)OR100, —C(O)NR100R101, —N(R100)C(O)R101, —CF3, —CN, —NO2, —N3, acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, alkylthio or substituted alkylthio;
alternatively, two of R4 groups or an R4 group with an R5 group together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted 3, 4, 5, 6 or 7 membered ring.

### Claim 6 (depends on 1)

A compound of claim 1 having the formula:

### Claim 7 (depends on 1)

A compound according to claim 1,
wherein Cy1 is selected from:
wherein w is 0, 1, 2, 3 or 4;
each R104 and R105 is independently selected from hydrogen, deuterium, halogen, alkyl, cycloalkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocycle, substituted heterocycle, heteroaryl, or substituted heteroaryl —OR100, —SR100, —S(O)—, S(O)2—, —S(O)2N(R100)(R101), —NR100R101, —C(O)R100, —C(O)OR100, —C(O)NR100R101, —N(R100)C(O)R101, —CF3, —CN, —NO2, —N3, acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, alkylthio or substituted alkylthio;
alternatively, two of R104 groups or an R104 group with an R105 group together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted 3, 4, 5, 6 or 7 membered ring, preferably a cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl group.

### Claim 8 (depends on 1)

A compound according to claim 1,
wherein Cy2 is selected from:
wherein w is 0, 1, 2, 3 or 4;
each R104 and R105 is independently selected from hydrogen, deuterium, halogen, alkyl, cycloalkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl —OR100, —SR100, —S(O)—, S(O)2—, —S(O)2N(R100)(R101), —NR100R101, —C(O)R100, —C(O)OR100, —C(O)NR100R101, —N(R100)C(O)R101, —CF3, —CN, —NO2, —N3, acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, alkylthio or substituted alkylthio;
alternatively, two of R104 groups or an R104 group with an R105 group together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted 3, 4, 5, 6 or 7 membered ring.

### Claim 9

A compound selected from Table 4:
TABLE 4

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a carrier.

### Claim 11

A method of treating a disease or disorder mediated by cystic fibrosis transmembrane conductance regulator (CFTR) comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:
wherein n is 0, 1, 2, 3, 4, 5, 6 or 7;
each X is independently selected from each X is independently selected from —CR100-5-N—, —COR100, —CN(R100)(R101), —CSR100, —C—C(O)NR100, and —CN(R100)C(O)R101;
A1 is absent, —[C(R100)(R101)]m— —C(O)—, —C(S)—, —S(O)—, —C(O)N(R100)— or —S(O)2—, —S(O)2N(R100)(R101), —N[C(R100)(R101)]m—, —N(R100)C(O)—, —N(R100)C(S)—, —N(R100)S(O)—, —N(R101)C(O)N(R100)— or —N(R100)S(O)2—, —N(R100)S(O)2N(R100)(R101);
wherein m is 0, 1, 2, 3, 4, 5, 6 or 7;
wherein each R100 and R101 is hydrogen, deuterium, halogen, alkyl, cycloalkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl and substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl or substituted heteroaryl; alternatively two of R100 and R101 groups together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;
A2 is absent, —[C(R100)(R101)]m— —C(O)—, —C(S)—, —S(O)—, —C(O)N(R100)— or —S(O)2—, —S(O)2N(R100)(R101);
each R1 is independently selected from hydrogen, deuterium, halogen, alkyl, cycloalkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl —OR100, —SR100, —S(O)—, S(O)2—, —S(O)2N(R100)(R101), —NR100R101, —C(O)R100, —C(O)OR100, —C(O)NR100R101, —N(R100)C(O)R101, —CF3, —CN, —NO2, —N3, acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, alkylthio or substituted alkylthio; alternatively two of R1 groups together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted 3, 4, 5, 6 or 7 membered ring;
Cy1 is absent, alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
Cy2 is alkyl, cycloalkyl, substituted cycloalkyl aryl, substituted aryl, heteroaryl or substituted heteroaryl.

### Claim 12 (depends on 1)

A method of treating a disease or disorder mediated by the cystic fibrosis transmembrane conductance regulator (CFTR) comprising the step of administering a therapeutically effective amount of a compound according to claim 1 to a patient in need thereof.

### Claim 13 (depends on 1)

A method for treating a condition, disease or disorder modulated by ABC transporter protein comprising the step of administering a compound according to claim 1 to a patient in need thereof.

### Claim 14 (depends on 13)

The method according to claim 13, wherein said condition, disease or disorder is selected from cystic fibrosis, Stargardt disease, age-related macular degeneration, adrenoleukodystrophy, Tangier disease, Dubin-Johnson syndrome and progressive familial intrahepatic cholestasis.

### Claim 15 (depends on 12)

The method according to claim 12, wherein said disease or disorder is selected from cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, diabetes mellitus, Laron dwarfism, myeloperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, hereditary emphysema, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, several polyglutamine neurological disorders such as Huntington's disease, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentororubal pallidoluysian, and Myotic dystrophy, as well as, spongiform encephalopathies such as Hereditary Creutzfeldt-Jakob disease, Fabry disease, Straussler-Scheinker disease, secretory diarrhea, polycystic kidney disease, chronic obstructive pulmonary disease (COPD), dry eye disease, or Sjogren's Syndrome.

### Claim 16 (depends on 1)

A method for treating cystic fibrosis or a symptom thereof, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

### Claim 17 (depends on 1)

A method for treating a condition, disease or disorder mediated by the CFTR gene comprising the step of administering a compound according to claim 1 to a subject in need thereof.

### Claim 18 (depends on 1)

A method for treating a condition, disease or disorder mediated by a mutation to CFTR gene selected form deltaF08, G542X, N13O3K, W1282X, R117H, R553X, D1152H, W1282X, R347P, R1070Q, splice mutations 1717-1G->A, 2789+5G->A, and 621+1G->T comprising the step of administering a compound according to claim 1 to a subject in need thereof.

### Claim 19 (depends on 12)

The method according to claim 12, wherein said compound is selected from claim Table 4.

### Claim 20 (depends on 1)

A composition comprising a compound according to claim 1 or a combination thereof, in combination with a compound selected from Gentamicin, Ataluren, Ivacaftor (Kalydeco) and VX-809 or a combination thereof.

### Claim 21 (depends on 1)

A composition according to claim 1 administered optionally in combination with a mucolytic, a bronchiodilator, an antibiotic, an anti-infective, an anti-inflammatory, a CFTR modulator, or a nutritional agent.
